Under pressure to rebuild as sales of its blockbuster Lantus slide, Sanofi desperately needed the launch of its Dengue vaccine to run smoothly. But it hasn’t. Analysts had expected blockbuster ...

Mosnodenvir is designed to block interactions between two dengue virus proteins. The vaccine survived J&J’s decision last ...

Sanofi’s is to pay back money to the Philippines government for unused doses of its Dengue fever vaccine, after serious safety concerns halted its use. Dengvaxia is the first vaccine of its kind ...

French pharmaceutical giant Sanofi Pasteur’s motion for reconsideration on a ruling related to its controversial Dengvaxia ...

There are currently no recommendations for anyone to be vaccinated against bird flu and federal health officials note this is ...

Introduction State of the Art Dengue Vaccine Development Challenges ... Live-attenuated vaccine based on YF-17D Acambis/Sanofi Pasteur Phase III Live-attenuated vaccine based on DENV2-PDK-53 ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu, Boucher said. Australia's CSL recently secured a contract worth $121.4 million to ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. The grant comes from the ...

GSK Plc, Sanofi, and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human ...

Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply (Reuters) -GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines ...